TORONTO, June 2 /CNW/ - Patheon (TSX:PTI), a leading global provider of
drug development and manufacturing services to the international
pharmaceutical industry, today announced a performance enhancement program and
its results for the second quarter ended April 30, 2006. (All amounts are in
U.S. dollars unless otherwise indicated.)
Performance Enhancement Program
"Our Board of Directors and management team are confident that Patheon
has established its position as a market leader in the pharmaceutical
outsourcing industry," said Mr. Peter Green, Chairman of Patheon Inc.
"However, we are dissatisfied with the Company's financial performance. It is
clear that now is the time to unlock the inherent economic value of the
Company through an immediate and aggressive plan to improve the profitability
and cash generation capability of our business model."
The Office of the Chief Executive Officer has initiated a performance
enhancement program, aimed at improving the productivity and cost
effectiveness of Patheon's operations.
"We are committed to swift and decisive action, and look forward to
reporting on our progress as we enter this new phase of Patheon's
development," said Mr. Green.
CEO Succession
The Board's Succession Committee is actively engaged in the search for
the new Chief Executive Officer and expects to complete the process during the
fourth quarter.
"In the meantime," Mr. Green said, "the Office of the Chief Executive
Officer is working closely with senior management to develop and implement the
performance enhancement program, with the objective of improving Patheon's
operational and financial strength, flexibility and profitability, both in the
short and longer term."
Company Financial Results
Second Quarter Ended April 30, 2006
Compared With Second Quarter Ended April 30, 2005
- Revenues increased 3% to $189.9 million;
- EBITDA was $24.2 million (12.8% of revenues) compared with
$24.3 million (13.2% of revenues);
- Net earnings were $3.0 million (3.2 cents per share), compared with
net earnings of $3.8 million (3.4 cents per share).
Six Months Ended April 30, 2006
Compared With Six Months Ended April 30, 2005
- Revenues increased 3% to $347.8 million;
- EBITDA was $38.2 million (11.0% of revenues), compared with
$45.9 million (13.6% of revenues);
- The net loss was $8.5 million or 9.2 cents per share compared with net
earnings of $9.8 million (12.1 cents per share).
"Our financial performance improved compared with the first quarter of
this year across most key measures, including revenues, EBITDA, and net
earnings," said Douglas L. Ludwig, Chief Financial Officer and Executive
Vice-President. "While we continue to view 2006 as a challenging year, we will
be focused on establishing the performance enhancement plan, with quantifiable
objectives and timetables that we will communicate to our stakeholders so that
our progress can be actively monitored."
Consolidated EBITDA of $24.2 million represented an increase of
$10.2 million over the first quarter of 2006, but was comparable to
$24.3 million in the second quarter of last year. As a percentage of revenues,
the EBITDA margin was 12.8% in the second quarter of 2006, compared with 13.2%
in the same period a year ago.
In North America, EBITDA from the Puerto Rico commercial manufacturing
operations was $4.4 million, declining 55% from the same period a year ago.
This decline was primarily attributable to lower revenues from a generic
product, where the Company's client lost a major customer, and additional
costs incurred as part of the corrective action plan to address FDA issues
relating to Omnicef(R) production. Volume declines at the Caguas and Manati
facilities were offset in part by improved revenue performance at Carolina,
where volumes exceeded those in the same period a year ago.
Higher capacity utilization at the Canadian commercial manufacturing
operations resulted in an increase in EBITDA over the same period a year ago
of $4.9 million, or 101%. The increases in Canada were driven by the Toronto
Region facility, where EBITDA of $9.2 million was $2.8 million higher than a
year ago, and the Whitby facility, which reported EBITDA of $1.8 million,
compared with a loss of $2.0 million in the same period a year ago. EBITDA
from commercial manufacturing operations at Cincinnati were comparable to
those in the same period a year ago.
In Europe, EBITDA from commercial manufacturing improved by 49% to
$7.5 million over the same period a year ago. This improvement was primarily
attributable to increased large-volume parenteral volumes at the Italian sites
resulting from one of two client carve-out initiatives underway in Europe, and
continued improved performance at Swindon, U.K.
EBITDA from the global PDS operations declined by 31% to $3.4 million in
the second quarter. Growth at the Cincinnati and Puerto Rico PDS units was
offset by lower earnings from the Canadian PDS operations, where there were
fewer late-stage projects and where the strengthening of the Canadian dollar
also had an impact.
Outlook
"Overall, we expect that revenues in the second half of 2006 will be
slightly higher than in the second half of 2005, but EBITDA will be similar,
due to the impact of the continuing strength of the Canadian dollar relative
to the U.S. dollar," said Mr. Ludwig. "This has the effect of reducing the
profitability of the Canadian operations, where most of the revenues are
denominated in US dollars, but costs are largely incurred in Canadian dollars.
Depreciation, amortization and interest costs will be marginally higher than
the second quarter run rate. Effective tax rates will be impacted largely by
changes in profitability of the Puerto Rico and Italian operations. Tax rates
in the third quarter are expected to be in the 50-55% range, falling to 40-45%
in the fourth quarter."
Business Development
During the second quarter, Patheon entered into a seven-year contract
with a major pharmaceutical company client to provide commercial manufacturing
services from its Swindon, U.K. facility for a promising innovative
cephalosporin product designed to be effective against methicillin-resistant
Staphylococcus aureus (MRSA). The client is planning to launch the product for
the U.S. market in 2007, subject to receiving FDA approval.
During the second quarter, Patheon also entered into a technology
transfer agreement with another major pharmaceutical company client to
transfer an existing commercial product to Patheon's Manati plant in Puerto
Rico. An agreement on a second product is also nearing completion. Long-term
manufacturing and supply agreements are under negotiation, and technical teams
are already working on the transfer of the products. PDS work on both of these
projects will take place throughout the balance of 2006 and early 2007, while
the majority of commercial revenues will be generated in 2007 and beyond.
Furthermore, the Manati facility is being qualified to handle additional
volumes of a recently launched product currently manufactured at Patheon's
Toronto facility. This will be of benefit to the client, who will have a dual
sourcing strategy and additional capacity for this important product. For
Patheon, it will enable the Toronto facility to take on more high-potency work
for which there is significant demand, and the Manati facility will gain from
the addition of new volumes.
"These and other important new sources of revenues will help to offset
declines in base business, including lower Zocor(R) production as its patent
expires in June 2006," said Nick DiPietro, President and Chief Operating
Officer.
FORWARD-LOOKING STATEMENTS
Cautionary Note
This news release contains forward-looking statements which reflect
management's expectations regarding the Company's future growth of operations,
performance (both operational and financial) and business prospects and
opportunities.
PLEASE REFER TO THE CAUTIONARY NOTE AT THE END OF THE MANAGEMENT
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
("MD&A") ATTACHED TO AND FORMING PART OF THIS NEWS RELEASE.
Patheon Inc. will host a webcast conference call with financial analysts
on its second quarter results on Friday, June 2, 2006 at 10:00 a.m. (Eastern
Daylight Time). Representing Patheon on the call will be: Peter Green,
Chairman, Patheon Inc.; Nick DiPietro, President and Chief Operating Officer;
Douglas Ludwig, Chief Financial Officer and Executive Vice-President; and
Shelley Jourard, Director, Corporate Communications. The call will begin with
a brief presentation, followed by a question-and-answer period with investment
analysts. Interested parties are invited to access the live call, via
telephone, in listen-only mode, at (416) 644-3433 (Toronto and International)
or toll free at (800) 814-4941 (U.S., including Puerto Rico). Listeners are
encouraged to dial in five to 15 minutes in advance to avoid delays. A live
audio webcast, with a slide presentation, will also be available via the web
at www.patheon.com. An archived version of the Q2 webcast will be available on
www.patheon.com for three months.
ABOUT PATHEON
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 6,100 people and serving a client base
of more than 200 pharmaceutical and biotechnology companies.
<<
Consolidated Statements of Earnings (Loss)
(unaudited)
Three months ended Six months ended
April 30, April 30,
2006 2005 % 2006 2005 %
change change
-------------------------------------------------------------------------
(in thousands
of U.S. dollars,
except per share
amounts) $ $ $ $
-------------------------------------------------------------------------
Revenues 189,902 184,088 3.2% 347,846 338,035 2.9%
Operating
expenses 165,689 159,802 3.7% 309,621 292,102 6.0%
------------------------- --------------------------
Earnings before the
following: 24,213 24,286 -0.3% 38,225 45,933 -16.8%
------------------------- --------------------------
(as a % of
revenues) 12.8% 13.2% 11.0% 13.6%
Depreciation and
amortization 9,920 8,858 12.0% 19,731 16,677 18.3%
Amortization of
intangible assets 3,472 3,244 7.0% 6,895 4,524 52.4%
Interest 4,795 4,681 2.4% 9,898 7,014 41.1%
Debt prepayment
charges (note 10) - - 1,643 -
Amortization of
deferred financing
costs 137 1,570 -91.3% 462 2,147 -78.5%
Write-off of deferred
financing costs
(note 10) - 16 -100.0% 6,332 2,010 215.0%
------------------------- --------------------------
Earnings (loss)
before income
taxes 5,889 5,917 -0.5% (6,736) 13,561 -149.7%
Provision for
income taxes 2,900 2,134 35.9% 1,785 3,774 -52.7%
------------------------- --------------------------
Net earnings (loss)
for the period 2,989 3,783 -21.0% (8,521) 9,787 -187.1%
------------------------- --------------------------
------------------------- --------------------------
(as a % of
revenues) 1.6% 2.1% -2.4% 2.9%
Earnings (loss)
per share
Basic 3.2 3.4 -5.9% (9.2) 12.1 -176.0%
cents cents cents cents
------------------------- --------------------------
Diluted 3.2 3.4 -5.9% (9.2) 12.1 -176.0%
cents cents cents cents
------------------------- --------------------------
Average number of
shares (note 3)
outstanding during
period:
Basic
(in thousands) 92,846 92,846 0.0% 92,846 80,710 15.0%
------------------------- --------------------------
Diluted
(in thousands) 93,110 93,384 -0.3% 92,846 81,152 14.4%
------------------------- --------------------------
see accompanying notes
Consolidated Statements of Retained Earnings
(unaudited)
Six months ended April 30,
2006 2005
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Retained earnings, beginning of the year 98,250 76,629
Net earnings (loss) for the period (8,521) 9,787
-----------------
Retained earnings, end of period 89,729 86,416
-----------------
-----------------
see accompanying notes
Consolidated Balance Sheets
(unaudited)
As at As at
April 30, October 31,
2006 2005
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Assets
Current
Cash and cash equivalents 6,227 22,507
Restricted cash - 7,805
Accounts receivable 129,608 143,646
Inventories 82,208 72,818
Income taxes receivable 5,125 -
Prepaid expenses and other 9,227 4,258
------------------------
Total current assets 232,395 251,034
------------------------
Capital assets 499,854 474,793
Intangible assets 109,179 110,095
Deferred costs 8,320 12,342
Future tax assets 32,657 21,368
Goodwill 190,878 180,665
Investment 1,317 1,271
------------------------
1,074,600 1,051,568
------------------------
------------------------
Liabilities and Shareholders' equity
Current
Bank indebtedness 1,776 14,357
Accounts payable and accrued liabilities 131,104 129,067
Income taxes payable - 5,650
Current portion of long-term debt (note 9) 17,491 11,360
------------------------
Total current liabilities 150,371 160,434
------------------------
Long-term debt (note 9) 274,682 277,181
Other long-term liabilities 23,833 22,755
Deferred revenues 24,127 14,587
Future tax liabilities 39,803 36,760
------------------------
Total liabilities 512,816 511,717
------------------------
Shareholders' equity
Share capital 400,594 400,594
Contributed surplus 3,393 2,901
Retained earnings 89,729 98,250
Cumulative translation adjustment 68,068 38,106
------------------------
Total shareholders' equity 561,784 539,851
------------------------
1,074,600 1,051,568
------------------------
------------------------
see accompanying notes
Consolidated Statements of Cash Flows
(unaudited)
Three months ended Six months ended
April 30, April 30,
2006 2005 2006 2005
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $ $ $
-------------------------------------------------------------------------
Operating activities
Net earnings (loss) for
the period 2,989 3,783 (8,521) 9,787
Add (deduct) charges to
operations not requiring
a current cash payment
Depreciation and
amortization 13,529 13,672 27,088 23,348
Write-off of deferred
financing costs (note 10) - 16 6,332 2,010
Employee future benefits 860 92 74 809
Future income taxes 459 175 2,774 282
Amortization of deferred
revenues (498) (381) (995) (338)
Other 373 348 871 843
---------------------------------------------
17,712 17,705 27,623 36,741
Net change in non-cash
working capital balances
related to operations (15,387) (14,563) (17,534) (13,145)
---------------------------------------------
Cash provided by operating
activities 2,325 3,142 10,089 23,596
---------------------------------------------
Investing activities
Acquisition - 636 - (145,190)
Cash acquired on acquisition - - - 645
---------------------------------------------
Acquisition net of cash
acquired - 636 - (144,545)
Increase in escrow cash
related to acquisition - - - (87,825)
Additions to capital
assets
- sustaining (3,597) (3,180) (6,337) (4,330)
- project - related (10,028) (9,683) (21,208) (21,996)
Decrease (increase) in
deferred pre-operating
costs 61 (995) (457) (2,054)
---------------------------------------------
Cash used in investing
activities (13,564) (13,222) (28,002) (260,750)
---------------------------------------------
Financing activities
Increase (decrease) in
bank indebtedness 905 (1,392) (12,691) (1,843)
Increase in long-term
debt 27,563 66,872 311,143 230,911
Repayment of long-term
debt (23,993) (55,775) (311,345) (159,160)
Decrease (increase) in
restricted cash - (187) 7,805 (447)
Increase in deferred
financing costs (25) (815) (2,790) (9,535)
Increase in deferred
revenues - - 9,614 -
Proceeds on issue of
common shares before
costs - - - 199,241
Share issue costs - (5) - (8,947)
---------------------------------------------
Cash provided by financing
activities 4,450 8,698 1,736 250,220
---------------------------------------------
Effect of exchange rate
changes on cash and cash
equivalents (225) (1,468) (103) (7,435)
---------------------------------------------
Net increase (decrease) in
cash and cash equivalents
during the period (7,014) (2,850) (16,280) 5,631
Cash and cash equivalents,
beginning of period 13,241 16,107 22,507 7,626
---------------------------------------------
Cash and cash equivalents,
end of period 6,227 13,257 6,227 13,257
---------------------------------------------
---------------------------------------------
see accompanying notes
Patheon Inc.
Notes to Unaudited Consolidated Financial Statements for the Six Months
Ended April 30, 2006
(Dollar information in tabular form is expressed
in thousands of U.S. dollars)
1. Accounting policies
The accompanying unaudited consolidated financial statements have been
prepared by Patheon Inc. (the "Company") in accordance with Canadian
generally accepted accounting principles on a basis consistent with those
followed in the most recent audited consolidated financial statements.
These consolidated financial statements do not include all the
information and footnotes required by generally accepted accounting
principles for annual financial statements and therefore should be read
in conjunction with the audited consolidated financial statements and
notes included in the Company's Annual Report for the year ended
October 31, 2005.
The Company has adopted Accounting Guideline 15 "Consolidation of
Variable Interest Entities". The Guideline requires consolidation of
entities that are deemed to be subject to control on a basis other than
through ownership of a voting interest in the entity. The Company has
concluded that it does not have any variable interest entities and there
is no impact on the financial statements as a result of adopting the
Guideline.
2. MOVA Acquisition
On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively
"MOVA"), a leading U.S. prescription pharmaceutical manufacturer located
in Puerto Rico, U.S.A.
The acquisition was accounted for using the purchase method and the
accompanying unaudited consolidated financial statements include the
results of operations from the date of purchase.
3. Average number of shares
The following is a reconciliation of the weighted average number of basic
and diluted shares:
Three months ended April 30,
2006 2005
---------------------------------------------------------------------
Weighted average number of common
shares outstanding 92,845,688 92,845,688
Effect of dilutive stock options 264,160 537,988
---------------------------------------------------------------------
Weighted average number of common
shares outstanding - diluted 93,109,848 93,383,676
---------------------------------------------------------------------
---------------------------------------------------------------------
Six months ended April 30,
2006 2005
---------------------------------------------------------------------
Weighted average number of common
shares outstanding 92,845,688 80,709,704
Effect of dilutive stock options - 442,631
---------------------------------------------------------------------
Weighted average number of common
shares outstanding - diluted 92,845,688 81,152,335
---------------------------------------------------------------------
---------------------------------------------------------------------
4. Share capital
The following table summarizes information on share capital and related
matters at April 30, 2006:
Outstanding Exercisable
Common shares 92,845,688
Common share stock options 4,252,979 3,553,801
5. Segmented information
The Company is organized and managed as a single business segment, being
the provider of commercial manufacturing and pharmaceutical development
services.
North American and European operations consist of:
Three months ended April 30, 2006
-------------------------------------------
Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 11,020 35 119 11,174
U.S.A. 40,218 64,970 1,902 107,090
Europe 15,290 74 53,324 68,688
Other geographic areas 1,289 90 1,571 2,950
-------------------------------------------------------------------------
Total revenues 67,817 65,169 56,916 189,902
-------------------------------------------------------------------------
Capital assets 129,453 170,819 199,582 499,854
-------------------------------------------------------------------------
Goodwill 3,091 187,787 - 190,878
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Three months ended April 30, 2005
-------------------------------------------
Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 6,262 383 660 7,305
U.S.A. 42,947 70,420 2,435 115,802
Europe 10,694 58 48,326 59,078
Other geographic areas 1,425 103 375 1,903
-------------------------------------------------------------------------
Total revenues 61,328 70,964 51,796 184,088
-------------------------------------------------------------------------
Capital assets 109,974 177,344 191,546 478,864
-------------------------------------------------------------------------
Goodwill 2,746 86,350 - 89,096
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Six months ended April 30, 2006
-------------------------------------------
Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 21,056 288 408 21,752
U.S.A. 73,595 120,283 3,928 197,806
Europe 25,295 335 97,640 123,270
Other geographic areas 2,503 171 2,344 5,018
-------------------------------------------------------------------------
Total revenues 122,449 121,077 104,320 347,846
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Six months ended April 30, 2005
-------------------------------------------
Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 12,445 546 1,154 14,145
U.S.A. 85,072 121,626 4,352 211,050
Europe 21,300 303 87,727 109,330
Other geographic areas 2,517 219 774 3,510
-------------------------------------------------------------------------
Total revenues 121,334 122,694 94,007 338,035
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Revenues are attributed to countries based on the location of the
client's billing address, capital assets are attributed to the country in
which they are located, and goodwill is attributed to the country in
which the entity to which the goodwill pertains is located.
Revenue information by service activity is as follows:
Three months ended April 30,
-------------------------------------------
2006 2005
$ $
-------------------------------------------------------------------------
Commercial manufacturing -
prescription 140,160 74% 132,710 72%
Commercial manufacturing -
over-the-counter 27,395 14% 29,249 16%
Development services 22,347 12% 22,129 12%
-------------------------------------------------------------------------
189,902 100% 184,088 100%
-------------------------------------------------------------------------
Six months ended April 30,
-------------------------------------------
2006 2005
$ $
-------------------------------------------------------------------------
Commercial manufacturing -
prescription 252,199 72% 238,954 70%
Commercial manufacturing -
over-the-counter 51,290 15% 55,931 17%
Development services 44,357 13% 43,150 13%
-------------------------------------------------------------------------
347,846 100% 338,035 100%
-------------------------------------------------------------------------
6. Stock-based compensation
The Company has an incentive stock option plan. Persons eligible to
participate in the plan are directors, officers, and key employees of the
Company and its subsidiaries or any other person engaged to provide
ongoing management or consulting services to Patheon. The plan provides
that the maximum number of shares that may be issued under the plan is
7.5% of the issued and outstanding common shares of the Company at any
point in time. At April 30, 2006, the total number of common shares
available for issuance under the plan was 6,963,427, of which 4,252,979
were reserved for options granted and outstanding under the plan. The
exercise price of common shares subject to an option is determined at the
time of grant and the price cannot be less than the weighted average
market price of the common shares of Patheon on the Toronto Stock
Exchange during the two trading days immediately preceding the grant
date. Options generally expire 10 years after the grant date and are also
subject to early expiry in the event of death, resignation, dismissal or
retirement of an optionee. Options generally vest over three years, one-
third on each of the first, second and third anniversary of the grant
date.
The fair value of stock options is estimated at the date of the grant.
The weighted average fair value of the 222,500 options granted for the
three months ended April 30, 2006 was $2.77 (2005-$2.94). The weighted
average fair value of stock options granted for the six months ended
April 30, 2006 was $2.30 (2005-$2.94). The fair value of stock options is
estimated at the date of grant using the Black-Scholes option pricing
model. The following assumptions were used in arriving at the fair value
of options issued during the three months ended April 30, 2006:
Risk free interest rate 4.3%
Expected volatility 42%
Expected weighted average life of the options 6 years
Expected dividend yield 0%
Stock-based compensation expense recorded in the three months ended
April 30, 2006 was $152,000 (2005 - $348,000) for options granted on or
after November 1, 2003. Stock based compensation expense recorded for the
six months ended April 30, 2006 was $492,000 (2005-$843,000) for options
granted on or after November 1, 2003.
Stock options granted prior to November 1, 2003 are accounted for using
the intrinsic value method, which does not give rise to compensation
expense. Had these stock options been accounted for at fair value, the
pro-forma net earnings (loss) and earnings (loss) per share would have
been:
Three months Six months
ended April 30, ended April 30,
2006 2005 2006 2005
--------------------------------------------------
$ $ $ $
--------------------------------------------------
Net earnings (loss)
as reported 2,989 3,783 (8,521) 9,787
Pro-forma adjustments
for the fair value
of stock options
granted prior to
November 1, 2003 (22) (47) (28) (98)
--------------------------------------------------
Pro-forma net earnings
(loss) 2,967 3,736 (8,549) 9,689
--------------------------------------------------
Pro-forma earnings
(loss) per share:
Basic 3.2 cents 3.4 cents (9.2 cents) 12.0 cents
Diluted 3.2 cents 3.3 cents (9.2 cents) 11.9 cents
7. Other information
Cumulative translation adjustment
The cumulative translation adjustment amount is impacted by fluctuations
in the value of the U.S. dollar relative to the Canadian dollar, the euro
and U.K. sterling.
Unrealized translation adjustments, which arise on the translation to
U.S. dollars of the Company's self-sustaining foreign operations,
resulted in an unrealized currency translation gain of $12,279,000 for
the three months ended April 30, 2006 (2005 - unrealized currency
translation loss of $5,308,000). For the six months ended April 30, 2006,
the unrealized currency translation gain is $29,962,000 (2005 -
unrealized currency translation loss of $6,496,000).
The net unrealized gain of $12,279,000 in the quarter and $29,962,000
year-to-date is attributable to the weakening of the U.S. dollar against
the Canadian dollar, the euro and U.K. sterling, as measured at April 30,
2006, January 31, 2006 and October 31, 2005.
Foreign exchange
During the three months ended April 30, 2006, the foreign exchange gain
was $441,000 (2005 gain - $1,116,000). For the six months ended April 30,
2006, the foreign exchange gain was $189,000 (2005 - $3,377,000)
Employee future benefits
The employee future benefit expense for the three months ended April 30,
2006 was $860,000 (2005 - $92,000). For the six months ended April 30,
2006, the employee future benefit expense was $74,000 (2005 - $809,000).
8. Financial instruments
The Company utilizes financial instruments to manage the risk associated
with fluctuations in foreign exchange rates and interest rates. The
Company formally documents all relationships between hedging instruments
and hedged items, as well as its risk management objective and strategy
for undertaking various hedge transactions.
The Company has entered into foreign exchange forward contracts with an
aggregate amount of US$35,000,000 as at April 30, 2006. These contracts
mature at the latest on September 27, 2006 at exchange rates varying
between 1.16996 and 1.1728 Canadian. The mark-to-market value on these
financial instruments as at April 30, 2006 was an unrealized gain of
US$1,449,000.
In the second quarter of 2006, the Company unwound its interest rate swap
contracts that exchanged a notional amount of US$107,500,000 of debt from
floating to fixed interest rates. The gain of $1,097,000 that was
realized on the unwinding of the swaps is being amortized to interest
expense over approximately six years, reflecting the maturity dates of
the original contracts.
9. Long-term debt
On December 15, 2005, the Company completed new credit facilities in
North America in the aggregate amount of $290,000,000 to refinance
existing debt of the Company and its U.S. subsidiaries including its
subsidiaries in Puerto Rico. The new facilities replaced (i) existing
credit facilities that were available to the Company's North American
operations including those that were established at the time of
acquisition of MOVA in December 2004, and (ii) debt of MOVA that was
assumed at the time of acquisition by the Company. The new credit
facilities comprise two term loans in the aggregate amount of
$215,000,000 and three year revolving facilities in an aggregate amount
of $75,000,000. The term loans consist of a five-year term loan of
$50,000,000 and a six-year term loan of $165,000,000. At April 30, 2006,
$2,000,000 was drawn on the revolving facilities. The new credit
facilities bear interest at floating rates based on bankers' acceptances,
Canadian and U.S. prime, U.S. base rate, or U.S. LIBOR, plus spreads
between 0.75% and 2.5%. The new facilities are collateralized by the
North American assets of Patheon and its subsidiaries, including those of
Puerto Rico.
On December 22, 2005, the Company's Italian subsidiary entered into a new
long-term debt facility. The new loan replaced four separate term loans
it had with an Italian bank. The new loan in the amount of
(euro) 28,500,000 ($33,856,000), bearing interest at floating rates based
on 3-month Euribor maturing in 2014, has equal semi-annual principal
payments over the term of the nine year loan, and is collateralized by a
mortgage over land and buildings.
10. Debt prepayment charges and write-off of deferred financing costs
During the first quarter of 2006, the Company incurred charges of
$1.6 million in connection with the cancellation and prepayment of
certain of its North American credit facilities. The Company also wrote
off $6.3 million in related deferred financing costs in the first quarter
of 2006.
During the first quarter of 2005, the Company wrote off deferred
financing costs of $2.0 million associated with commitment fees paid for
financing that was not required in connection with the MOVA acquisition.
11. Contingent liability
During the second quarter of 2006, MOVA received a notice from the Puerto
Rico Industrial Development Company ("PRIDCO") requesting the accelerated
repayment of a grant that MOVA received in 1996. In accordance with the
terms of the original agreement with PRIDCO, MOVA has been repaying the
grant in the form of royalty payments that are tied to revenues generated
from specific products that MOVA manufactures for its clients. Such
royalty payments are charged to earnings as they are incurred.
The Company is in the process of investigating whether the accelerated
repayment of the grant is the responsibility of the previous owners of
MOVA. Because of the uncertainty of the outcome of these investigations,
no liability has been recorded on the balance sheet at April 30, 2006.
The amount outstanding on the grant at April 30, 2006 is $4,749,000.
12. Comparative amounts
Certain of the comparative amounts have been reclassified to conform to
the current period presentation.
Patheon Inc.
Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following management discussion and analysis of financial condition
and results of operations ("MD&A) of Patheon Inc. ("Patheon" or "the Company")
for the three-month and six-month periods ended April 30, 2006 and 2005 should
be read in conjunction with the Company's consolidated financial statements
and related notes contained in this interim report. This MD&A is dated as of
June 2, 2006.
The purpose of this 2006 second quarter report is to provide an update to
the information contained in the Management's Discussion and Analysis section
of the Company's 2005 Annual Report, which contains a more comprehensive
discussion of Company's strategy, capabilities to deliver results, risks and
key performance indicators. Management assumes that the reader of this
document has access to the MD&A section of the Company's 2005 Annual Report.
This document and other information can be downloaded in portable document
format (PDF) from the Company's web site at www.patheon.com or from the SEDAR
web site for Canadian regulatory filings at www.sedar.com. To request a
printed copy, the reader may also contact Patheon's transfer agent,
Computershare Trust Company of Canada, at 1-800-564-6253 or via email at
service(at)computershare.com, or Patheon at www.patheon.com.
Use of Non-GAAP Financial Measures
Except as otherwise indicated, references in this MD&A to "EBITDA" are to
earnings before depreciation and amortization, interest, debt prepayment
charges, write-off of deferred financing costs and income taxes. "EBITDA
margin" is EBITDA divided by revenues. EBITDA and EBITDA margin are measures
of earnings or earnings margin not recognized by generally accepted accounting
principles in Canada ("Canadian GAAP"). Since each of these measures is a
non-GAAP measure that does not have a standardized meaning, it may not be
comparable to similar measures presented by other issuers. Prospective
investors are cautioned that these, and other non-GAAP measures should not be
construed as alternatives to net earnings determined in accordance with
Canadian GAAP as indicators of performance. The Company has included these
measures because it believes that this information is used by certain
investors to assess financial performance.
Overview of Patheon
Patheon is focused exclusively on providing commercial manufacturing and
pharmaceutical development services to pharmaceutical, biotechnology and
specialty pharmaceutical companies located primarily in North America, Europe
and Japan. Patheon serves its international clientele from its operating
facilities in North America (including Puerto Rico) and Europe.
Patheon commercially manufactures prescription ("Rx") and
over-the-counter ("OTC") products in solid, semi-solid and liquid dosage forms
and manufactures Rx products in various sterile dosage forms. Conventional
dosage forms include compressed tablets, hard-shell capsules, powders,
ointments, creams, gels, syrups, suspensions, solutions and suppositories.
Sterile dosage forms include liquids filled in ampoules, vials, bottles or
pre-filled syringes. Sterile lyophilized products are also manufactured in
both vials and ampoules.
Patheon provides manufacturing services for a broad range of products in
many dosage forms and packaging formats in accordance with client
specifications. Depending on the particular client, Patheon may be responsible
for most or all aspects of the manufacturing and packaging process, from
sourcing excipient raw materials and packaging components to delivering the
finished product in consumer-ready form to the client. Typically, Patheon's
clients supply the active pharmaceutical ingredients ("API") used in the
production process.
The pharmaceutical development services provided by Patheon include most
of the pharmaceutical development services typically required by companies
conducting clinical trials and preparing for full-scale commercial production
of a new drug.
At April 30, 2006, there were a total of 158 client products in the
Patheon's pharmaceutical development services ("PDS") pipeline, including five
drug candidates at the New Drug Application ("NDA") stage. This compares with
a total of 128 client products a year ago. During the second quarter, one
product being developed on behalf of a client received regulatory approval and
was launched from the Company's facilities.
Vision and Strategy
Patheon's vision is to be the leader in pharmaceutical manufacturing.
Patheon strives to be the preferred manufacturing and pharmaceutical
development services partner to the global pharmaceutical industry. Patheon's
strategy is to offer strategic benefits to its clients by providing
comprehensive, high-quality and integrated manufacturing services throughout
the product lifecycle.
Patheon expects that stronger manufacturing and development relationships
will continue to emerge between pharmaceutical companies and service companies
as the pharmaceutical industry continues to re-evaluate its internal
manufacturing capabilities and streamlines its external service-provider
network. The Company is using its position as a comprehensive provider of
commercial manufacturing services to establish and maintain long-term and
strategic relationships with clients on a global basis.
The development of Patheon's business in recent years has been guided by
a plan to expand capacity, expertise and capabilities, positioning the Company
to be the preferred manufacturing services partner to the pharmaceutical
industry. This has led to the acquisition of several pharmaceutical
manufacturing facilities and the entry into long-term manufacturing
relationships in conjunction with certain of these acquisitions. In addition
to this strategic growth, Patheon is focused on growing the business
internally, by expanding the level of business from existing clients,
attracting new clients and entering into commercial manufacturing agreements
for newly approved products for which the Company has provided development
services.
In implementing its strategy, the Company will continue to maximize
capacity utilization and improve efficiency, broaden its services to include
other manufacturing capabilities and seek to increase the percentage of more
profitable products manufactured at its facilities. In addition, the Company
will seek to expand its PDS capabilities in North America and Europe to better
serve the needs of the global pharmaceutical industry. Pharmaceutical
development services are an important source of new business for commercial
manufacturing of prescription pharmaceuticals.
Key Performance Drivers
In Patheon's 2005 Annual Report, several key performance drivers were
identified for the Company: (i) increasing the percentage of more profitable
Rx products at its facilities; (ii) expanding its PDS capabilities in North
America and Europe; (iii) improving capacity utilization at the Company's
sites, which have a largely fixed-cost base in the short term; and (iv)
mitigating the impact of changes in the foreign exchange trading relationship
between the Canadian and U.S. dollar, since the Company's contracts in North
America are primarily denominated in U.S. dollars, but the operating expenses
of its six Canadian sites are primarily denominated in Canadian dollars. An
update on our interim performance relating to these key measures is provided
in the section below entitled "Results of Operations."
Acquisition of MOVA in the first quarter of 2005
On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively "MOVA", or
the "Puerto Rico operations"), a leading U.S. prescription pharmaceutical
contract manufacturer located in Puerto Rico, U.S.A.
The acquisition was accounted for using the purchase method and the
accompanying unaudited consolidated financial statements include the results
of operations from the date of purchase.
Results of Operations
Three Months Ended April 30, 2006 Compared with Three Months
Ended April 30, 2005
Revenues by Geographic Region and Service Activity
Three months ended Six months ended
April 30, April 30,
2006 2005 % 2006 2005 %
change change
------------------------------------------------------
North America
-------------
Commercial
Manufacturing
Prescription 88,231 85,891 3% 157,534 154,256 2%
Over-the-counter 26,900 28,877 -7% 50,419 54,995 -8%
------------------------------------------------------
115,131 114,768 0% 207,953 209,251 -1%
Development
Services 17,855 17,524 2% 35,573 34,777 2%
------------------------------------------------------
132,986 132,292 1% 243,526 244,028 0%
------------------------------------------------------
Europe
------
Commercial
Manufacturing
Prescription 51,929 46,819 11% 94,665 84,698 12%
Over-the-counter 495 372 33% 871 936 -7%
------------------------------------------------------
52,424 47,191 11% 95,536 85,634 12%
Development
Services 4,492 4,605 -2% 8,784 8,373 5%
------------------------------------------------------
56,916 51,796 10% 104,320 94,007 11%
------------------------------------------------------
TOTAL
-----
Commercial
Manufacturing
Prescription 140,160 132,710 6% 252,199 238,954 6%
Over-the-counter 27,395 29,249 -6% 51,290 55,931 -8%
------------------------------------------------------
167,555 161,959 3% 303,489 294,885 3%
Development
Services 22,347 22,129 1% 44,357 43,150 3%
------------------------------------------------------
CONSOLIDATED
REVENUES 189,902 184,088 3% 347,846 338,035 3%
------------------------------------------------------
------------------------------------------------------
Revenues
Consolidated revenues for the three-month period ended April 30, 2006
increased 3%, or $5.8 million, to $189.9 million from $184.1 million in the
same period in 2005. In the second quarter, growth came principally from Rx
commercial manufacturing services in both North America and Europe. On a
consolidated basis, commercial manufacturing revenues grew 3%, with Rx
manufacturing up 6%, offset in part by a 6% decline in OTC manufacturing
revenues compared with the second quarter of 2005. PDS revenues were
comparable with the same period in 2005.
Prescription manufacturing and development services represented 86% of
revenues, compared with 84% for the comparable period in 2005, a result of the
Company's focus on attracting more profitable Rx manufacturing and PDS
business to its facilities.
Geographically, in North America, revenue growth in the second quarter
was limited to $0.7 million or 1% over the same period a year ago. Revenues
from the Puerto Rico operations were $38.6 million, down from $45.1 million in
the same period a year ago, but up sequentially from $29.4 million in the
first quarter of 2006. The declines reflect a reduction in base business at
Caguas and Manati. Revenues from one generic product alone, where the
Company's client lost a major customer, accounted for most of this decline.
The Carolina operations, that were impacted by a voluntary shut down in
production of Omnicef(R) oral powder for suspension during the first quarter
of 2006 to address issues identified in a Warning Letter from the U.S. Food
and Drug Administration, showed marked improvement during the second quarter,
with revenues exceeding the same period last year. This product is now being
manufactured on three production lines and volumes have returned to
pre-Warning Letter levels.
Revenues from the existing operations in North America were $7.2 million,
or 8% higher than the same period last year, including a $9.7 million, or 23%
increase in Rx revenues. Revenues from the Toronto Region operations increased
principally as a result of two products that the Company launched for clients
in 2005, along with additional volumes from a range of oral contraceptives.
Revenues also increased at Whitby, as the site started to see improvements in
manufacturing efficiencies. These gains were partially offset by lower OTC
business in both Canada and Cincinnati.
Revenues from PDS services in North America increased 2% over the same
period a year ago as growth in the business in Cincinnati and Puerto Rico was
partially offset by lower revenues in Canada, where there were fewer
late-stage higher value projects than in 2005.
In Europe, revenues for the second quarter of 2006 were $5.1 million or
10% higher than the same period of 2005. The year-over-year increase in
revenues is due to improved commercial revenues at the two Italian sites and
Swindon, U.K. In the case of Italy the improvements reflect volume increases
from a carve-out project where the Company is manufacturing a range of
products for a client that is re-aligning its own manufacturing network, and
from increased sterile lyophilization volumes. The revenue increase in
Swindon, UK reflects services being provided in connection with the
lyophilized cephalosporin product that the Company will be launching for a
client. European currencies weakened against the U.S. dollar in the second
quarter of fiscal 2006 compared with the prior year. The euro weakened
approximately 7% and U.K. sterling weakened approximately 8% against the U.S.
dollar, reducing reported revenues by approximately $4.6 million. Had European
currencies remained constant to the rates of the prior year, European revenues
would have been 19% higher than the same period in 2005.
Operating Expenses
Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the second quarter of 2006, operating
expenses were $165.7 million, compared with $159.8 million in the same period
a year ago, an increase of 4%. The increase principally reflects the higher
revenue base, annual payroll-related increases, additional GMP-related costs
in Carolina and the impact of the strengthening Canadian dollar relative to
the U.S. dollar. These increases were offset in part by lower bonus costs,
savings from global procurement initiatives and from weakening European
currencies relative to the U.S. dollar. Operating expenses as a percentage of
revenues were 87.2%, compared with 86.8% in the same period a year ago.
EBITDA and EBITDA Margin
On a consolidated basis in the second quarter of 2006, EBITDA,
representing earnings before depreciation and amortization, interest, debt
prepayment charges, write-off of deferred financing costs and income taxes was
$24.2 million, compared with $24.3 million in the same period a year ago. As a
percentage of revenues, the EBITDA margin was 12.8% in the three-month period,
compared with 13.2% in the same period a year ago.
EBITDA from the Puerto Rico commercial operations was $4.4 million
representing a decline of 55% relative to the same period last year. This
reflects volume declines in Caguas and Manati, offset in part by the improved
performance in Carolina.
The profitability of Canadian operations was impacted by the
strengthening of the Canadian dollar relative to the U.S. dollar. The Canadian
dollar strengthened by approximately 7% relative to the second quarter of
2005. Had exchange rates remained the same as last year, EBITDA from the
Canadian operations, net of hedging activities, would have been approximately
$1.6 million higher than was reported.
Higher capacity utilization at the Canadian and European commercial
manufacturing operations resulted in an EBITDA increase over the prior year of
$4.9 million, or 101% and $2.4 million, or 49% respectively. The increases in
Canada were driven by the Toronto Region facility, where EBITDA of
$9.2 million was $2.8 million higher than 2005 and the Whitby facility, which
reported EBITDA of $1.8 million, compared with an EBITDA loss of $1.9 million
and $2.0 million in the first quarter of 2006 and the second quarter of 2005,
respectively.
EBITDA from the PDS operations was $1.6 million, or 31% lower than the
same period in 2005. The Canadian operations were negatively impacted by lower
revenues and from the continuing strengthening of the Canadian dollar against
the U.S. dollar.
Depreciation and Amortization Expense
Depreciation and amortization expense was $9.9 million in the second
quarter of 2006, compared with $8.9 million in the second quarter of 2005, an
increase of $1.0 million, or 12%. The increase principally reflects completed
capital programs in the Italian sites and from the Toronto Region operations.
Depreciation and amortization expense includes the amortization of deferred
pre-operating costs.
Amortization of Intangible Assets
Amortization of intangible assets was $3.5 million in the second quarter
of 2006, compared with $3.2 million for the second quarter of 2005. The
amortization of intangible assets relates entirely to the Puerto Rico
operations.
Interest Expense
Interest expense for the second quarter of 2006 was $4.8 million and was
comparable with the $4.7 million charge in the second quarter of 2005.
Amortization of Deferred Financing Costs
Amortization of deferred financing costs in the second quarter of 2006
was $0.1 million, compared with $1.6 million in the second quarter of 2005.
The charges in both years relate principally to the amortization of costs
associated with the North American credit facilities. The Company consolidated
its North American borrowing requirements in new credit facilities that were
completed during the first quarter of 2006. All unamortized costs associated
with the old facilities were charged to earnings at the time the new facility
was put in place.
Earnings Before Income Taxes
The Company reported earnings before income taxes of $5.9 million, which
was comparable with the amount reported in the same period a year ago.
Income Taxes
The effective tax rate on earnings before income taxes in the second
quarter of 2006 was 49.2% compared with an effective tax rate of 36.1% in the
same period a year ago. The increase in tax rates reflects a pre-tax loss in
the Puerto Rico operations, where the Company's tax rate averaged 5% and
increased earnings from Italian operations, where the effective tax rate
averaged 59%.
Net Earnings and Earning Per Share
The Company recorded net earnings in the second quarter of 2006 of
$3.0 million, compared with net earnings of $3.8 million in the same period
last year. The earnings per share were 3.2 cents, comparable with earnings per
share of 3.4 cents a year earlier. The diluted earnings per share were 3.2
cents compared with 3.4 cents in the second quarter of 2005. Dilution arises
solely from options issued under the Company's stock option plan.
Six Months Ended April 30, 2006 Compared with Six Months Ended
April 30, 2005
The results for the six-month period ended April 30, 2006 include the
operations of MOVA for a full two quarters, while the results of the
comparative period include the operations of MOVA from the date of acquisition
on December 23, 2004 until April 30, 2005.
Revenues
Consolidated revenues for the six-month period ended April 30, 2006
increased 3% or $9.8 million to $347.8 million from $338.0 million in the same
period in 2005. In the six-month period, growth was driven by Rx manufacturing
and PDS. On a consolidated basis, Rx manufacturing revenues grew 6% and PDS
revenues were up 3%. Offsetting this was a decline in OTC manufacturing
revenues of 8%.
Revenues from the Puerto Rico operations were $68.0 million, or
$1.0 million lower than 2005. The 2006 results include a full first quarter of
operations compared with only five weeks of operations in 2005. Revenues in
the second quarter were $6.5 million lower than prior year. The 2006 year-to-
date revenues in Puerto Rico reflect the impact of the temporary suspension of
production in the Carolina facility during the first quarter to resolve issues
identified in a Warning Letter from the U.S. Food and Drug Administration and
from declines in base business volumes in Caguas and Manati.
Excluding the Puerto Rico operations, growth from existing sites was
$10.8 million, or 4%, in the six-month period of 2006. Virtually all of this
increase was derived from the European operations. The growth in Europe was
attributable principally to Rx manufacturing services, which were up
$10.0 million, or 12% compared with the same period in 2005.
Prescription manufacturing and development services represented 85% of
revenues, compared with 83% for the comparable period in 2005, a result of
internal growth in Rx and PDS services and the inclusion of a full two
quarters of MOVA, where commercial services are all Rx. OTC revenues declined
8% in the first six months of 2006, as compared with the same period a year
ago, reflecting a continued decline in demand for these manufacturing services
at the Canadian OTC sites and Cincinnati. PDS six-month revenue growth was 3%
overall; 2% in North America and 5% in Europe, as compared with the same
period a year ago.
Geographically, North American revenues were $243.5 or $0.5 million lower
than the same period in the prior year. The decrease reflects a net decline in
revenue from the Puerto Rico operations of $1.0 million and lower OTC volumes
in both Canada and Cincinnati, offset by significant increases in volumes from
the Toronto Region high-potency facility, principally as a result of two
products that the Company launched for clients in 2005, along with additional
volumes from a range of oral contraceptives.
In Europe, revenues for the first six months of 2006 were 11% higher than
the same period of 2005. The increase reflects higher Rx manufacturing
revenues from the Italian and UK operations. European currencies weakened
against the U.S. dollar in the first six months of fiscal 2006 compared with
the prior year. The euro weakened approximately 8% and the British sterling
weakened approximately 7% against the U.S. dollar, reducing reported revenues
by approximately $9.2 million. Had European currencies remained constant to
the rates of the prior year, European revenues would have been 21% higher than
the same period in 2005.
Operating Expenses
Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the first six months of 2006,
operating expenses were $309.6 million, compared with $292.1 million in the
same period a year ago, an increase of 6%. The increase principally reflects
an additional seven weeks of operations in Puerto Rico, the higher revenue
base, annual payroll-related increases, additional GMP-related costs in
Carolina and the impact of the strengthening Canadian dollar relative to the
U.S. dollar. These increases were offset in part by lower bonus costs, savings
from global procurement initiatives and from weakening European currencies
relative to the U.S. dollar.
Operating expenses as a percentage of revenues were 89.0%, compared with
86.4% in the prior year. Excluding the impact of the Puerto Rico operations,
operating expenses as a percentage of revenue were 87.8% compared with 90.0%
in the same period a year ago. The improvement in margins in the existing
operations principally reflects the higher capacity utilization.
EBITDA and EBITDA Margin
On a consolidated basis in the first six months of 2006, EBITDA,
representing earnings before depreciation and amortization, interest, debt
prepayment charges, write-off of deferred financing costs and income taxes was
$38.2 million, a decline of $7.7 million, or 17%, from the comparable period
in 2005. As a percentage of consolidated revenues, EBITDA was 11.0% in the
six-month period, compared with 13.6% in the same period a year ago.
EBITDA from the Puerto Rico commercial operations was $3.3 million,
representing a decline of $15.5 million compared with the same period last
year. This reflects declines in base business volumes in Caguas and Manati and
the impact of the shut down in production in Carolina during the first quarter
of 2006.
On a year-to-date basis the Canadian dollar has strengthened by
approximately 5% relative to the same period last year. Had the exchange rate
remained the same as last year, EBITDA from the Canadian operations, net of
hedging activities, would have been approximately $2.2 million higher than was
reported.
Higher capacity utilization at the European commercial operations
resulted in an EBITDA increase over the prior year of $8.2 million, or 136%.
EBITDA in the Canadian commercial operations was $1.3 million, or 11% higher
than the same period last year as improvements in the Toronto Region and
Whitby operations were partially offset by declining profitability in the OTC
sites and from the impact of the strengthening Canadian dollar.
EBITDA from PDS operations was $2.7 million, or 25% lower than 2005 as
the Canadian operations were negatively impacted by lower revenues and from
the continuing strength in the Canadian dollar.
Depreciation and Amortization Expense
Depreciation and amortization expense was $19.7 million in the first six
months of 2006, compared with $16.7 million in the same period of 2005, an
increase of $3.0 million, or 18%. Of the increase, $1.1 million is
attributable to additional amounts relating to depreciation of the MOVA assets
in the first quarter of 2006 compared with the same period last year. The
remaining increase is attributable to completion of capital programs, in
particular at the Italian sites and the Toronto Region operations.
Depreciation and amortization expense includes the amortization of deferred
pre-operating costs.
Amortization of Intangible Assets
The amortization of intangible assets was $6.9 million in the first six
months of 2006, compared with $4.5 million in the first six months of 2005.
The amortization of intangible assets relates to the Puerto Rico operations.
The increase was due to the inclusion of a full quarter of amortization in the
first quarter of 2006, compared with five weeks in the first quarter of 2005.
Interest Expense
Interest expense for the first six months of 2006 was $9.9 million
compared with $7.0 million in the same period a year ago. The increase of
$2.9 million, compared with the prior year, was attributable to the inclusion
of a full quarter of interest expense in the first quarter of 2006 related to
the additional debt associated with the MOVA acquisition, compared with five
weeks in the first quarter of 2005.
Debt Prepayment Charges and Write-off of Deferred Financing Costs
During the first quarter of 2006, the Company incurred charges of
$1.6 million in connection with the cancellation and prepayment of certain of
its North American credit facilities. The Company also wrote off $6.3 million
in related deferred financing costs.
During the first quarter of 2005, the Company wrote off deferred
financing costs of $2.0 million associated with commitment fees paid for
financing that was not required in connection with the MOVA acquisition.
Amortization of Deferred Financing Costs
Amortization of deferred financing costs in the first six months of 2006
was $0.5 million, compared with $2.1 million in the same period of 2005. The
decrease reflects lower amortization charges associated with the Company's new
North American financing facilities that were completed on December 15, 2005.
Earnings (Loss) Before Income Taxes
The Company reported a loss before income taxes of $6.7 million in the
first six months of 2006, compared with earnings before income taxes of
$13.6 million in the same period a year ago.
Income Taxes
The income tax expense for the six months ended April 30, 2006 was
$1.8 million despite a loss before taxes of $6.7 million. This compares with a
tax charge of $3.8 million and an effective tax rate of 27.8% for the same
period a year ago. In 2006 the Company has incurred pre tax losses from the
Puerto Rico operations, where the effective tax rate averaged 5%. This
compares with a significant pre-tax profit for the same period last year. In
addition, pre-tax earnings in higher tax jurisdictions, in particular Italy,
were higher than in 2005.
Net Earnings (Loss) and Earnings (Loss) Per Share
The Company recorded a net loss in the first six months of 2006 of
$8.5 million, compared with net earnings of $9.8 million in the same period a
year ago. The loss per share was 9.2 cents compared with earnings per share of
12.1 cents a year earlier. The net loss in the first six months of 2006
included one-time after tax costs for debt prepayment charges and the
write-off of deferred financing costs of $6.2 million, or 6.6 cents per share.
The net earnings in the first half of 2005 included one-time after tax costs
for the write-off of deferred financing costs of $1.3 million, or 1.9 cents
per share.
The diluted loss per share was 9.2 cents compared with diluted earnings
per share of 12.1 cents in the first six months of 2005. Dilution arises
solely from options issued under the Company's stock option plan.
The average number of shares outstanding during the six-month period of
2006, determined on the basic and diluted bases, was 15% and 14% higher,
respectively than for the same period last year. The increase is the result of
shares issued in the first quarter of 2005 in connection with the MOVA
acquisition.
Seasonal Variability of Results
Typically, the Company's manufacturing and PDS revenues are lower in the
first fiscal quarter. While this pattern was followed in 2006, in the first
quarter of 2005 the Company experienced high revenues in its North American
commercial and PDS operations and in European PDS.
Liquidity and Capital Resources
Summary of Cash Flows
The following table summarizes the Company's cash flows for the periods
indicated:
Three months ended Six months ended
April 30, April 30,
2006 2005 2006 2005
--------------------- ---------------------
$ $ $ $
--------------------- ---------------------
Net earnings (loss) 2,989 3,783 (8,521) 9,787
Depreciation and
amortization 13,529 13,672 27,088 23,348
Write-off of deferred
financing costs - 16 6,332 2,010
Employee future benefits 860 92 74 809
Future income taxes 459 175 2,774 282
Amortization of deferred
revenues (498) (381) (995) (338)
Other 373 348 871 843
Working capital (15,387) (14,563) (17,534) (13,145)
--------- --------- --------- ---------
Cash provided by
operating activities 2,325 3,142 10,089 23,596
Cash provided by financing
activities 4,450 8,698 1,736 250,220
Cash used in investing
activities (13,564) (13,222) (28,002) (260,750)
Other (225) (1,468) (103) (7,435)
--------- --------- --------- ---------
Net increase (decrease) in
cash and cash equivalents (7,014) (2,850) (16,280) 5,631
--------- --------- --------- ---------
--------- --------- --------- ---------
Cash Provided by Operating Activities
Cash provided by operating activities was $2.3 million in the second
quarter of 2006 compared with $3.1 million for the comparable period in 2005.
On a year-to-date basis, cash provided by operating activities was
$10.1 million, compared with $23.6 million in the first half of 2005. The
year-to-date decrease reflects lower earnings before non-cash charges.
Cash Used in Investing Activities
Cash used in investing activities for the second quarter of 2006 was
$13.6 million, compared with $13.2 million in the same period a year ago.
Cash used in investing activities for the first six months ended
April 30, 2006 was $28.0 million, compared with $260.8 million in the same
period of 2005. The 2005 amount included cash used in connection with the
acquisition of MOVA of $232.4 million.
On a year-to-date basis, additions to capital assets in 2006 were
$27.5 million, compared with $26.3 million in 2005. The major capital project
in 2006 relates to the construction of a new 65,000 square foot facility in
Swindon, U.K. that will be dedicated to the manufacture of a new lyophilized
cephalosporin product for an established client. Year-to-date spending on this
project is $10.0 million. The project is planned to be completed in 2007. Year
to date the Company has also spent $1.6 million on the establishment of
high-potency capabilities in Bourgoin-Jallieu, France. Further spending on
this project will be deferred until 2007, to align with the client's revised
timing requirements for the capability.
A summary of cash used in investing activities is as follows:
Three months ended Six months ended
April 30, April 30,
2006 2005 2006 2005
--------------------- ---------------------
$ $ $ $
--------------------- ---------------------
Acquisition net of cash
acquired - (636) - 144,545
Increase in escrow cash
related to acquisition - - - 87,825
Additions to capital assets
-sustaining 3,597 3,180 6,337 4,330
-project-related 10,028 9,683 21,208 21,996
Increase (decrease) in
deferred pre-operating
costs (61) 995 457 2,054
--------- --------- --------- ---------
Cash used in investing
activities 13,564 13,222 28,002 260,750
--------- --------- --------- ---------
--------- --------- --------- ---------
Cash Provided by Financing Activities
The principal financing activities for the six months ended
April 30, 2006 were the completion of new credit facilities in North America
in the aggregate amount of $290.0 million to refinance existing debt of the
Company and its U.S. subsidiaries, completed during the first quarter. The
Company was able to release $7.8 million of restricted cash that had
previously been held as security for certain of the cancelled facilities. The
Company also incurred costs in connection with the refinancing of
$2.6 million.
During the first quarter of 2006 the Company's Italian subsidiary also
entered into a new long-term debt facility in the amount of 28.5 million euros
($33.9 million) to replace existing loans.
During the first quarter of 2006 the Company received $9.6 million from a
client for the reimbursement of costs the Company is incurring in connection
with the sterile cephalosporin lyophilization capacity being installed in
Swindon, U.K. This amount is recorded as an increase in deferred revenues.
A summary of cash provided by financing activities is as follows:
Three months ended Six months ended
April 30, April 30,
2006 2005 2006 2005
--------------------- ---------------------
$ $ $ $
--------------------- ---------------------
Increase (decrease) in bank
indebtedness 905 (1,392) (12,691) (1,843)
Increase in long-term debt 27,563 66,872 311,143 230,911
Repayment of long-term debt (23,993) (55,775) (311,345) (159,160)
Decrease (increase) in
restricted cash - (187) 7,805 (447)
Increase in deferred
financing costs (25) (815) (2,790) (9,535)
Increase in deferred revenues - - 9,614 -
Proceeds on issue of common
shares before costs - - - 199,241
Share issue costs - (5) - (8,947)
--------- --------- --------- ---------
Cash provided by financing
activities 4,450 8,698 1,736 250,220
--------- --------- --------- ---------
--------- --------- --------- ---------
Financing Arrangements and Ratios
At April 30, 2006, the Company's consolidated ratio of interest-bearing
debt to shareholders' equity was 52.3%, compared with 68.5% at April 30, 2005
and 56.1% at the end of the 2005 fiscal year. The improvement relative to the
second quarter of 2005 reflects the repayments of long-term debt financed from
the release of $22.8 million held in escrow in connection with the MOVA
acquisition during the third quarter of 2005, the release of $7.8 million in
restricted cash during the first quarter of 2006 and reduced cash balances.
On December 15, 2005, the Company completed new credit facilities in
North America in the aggregate amount of $290.0 million to refinance existing
debt of the Company and its U.S. subsidiaries, including its subsidiaries in
Puerto Rico. The new facilities replace: (i) existing credit facilities that
were available to the Company's North American operations, including those
that were established at the time of acquisition of MOVA in December 2004; and
(ii) debt of MOVA that was assumed at the time of acquisition by the Company.
The new credit facilities comprise two term loans in the aggregate amount of
$215.0 million and three-year revolving facilities in the aggregate totaling
$75.0 million. The term loans consist of a five-year term loan of
$50.0 million and six-year term loan of $165.0 million. At April 30, 2006, the
Company was drawing $2.0 million on the revolving facilities. The new
facilities are secured by the North American assets of Patheon and its
subsidiaries, including those in Puerto Rico.
On December 22, 2005, the Company's Italian subsidiary entered into a new
long-term debt facility. The new loan replaced four separate term loans it had
with an Italian bank. The new loan in the amount of 28.5 million euros
($33.9 million) is collateralized by a mortgage over land and buildings.
Adequacy of Financial Resources
The Company believes that its financial resources are sufficient to fund
projected capital expenditures and debt service requirements in the normal
course of business.
Contingent Liability
During the second quarter of 2006, MOVA received a notice from the Puerto
Rico Industrial Development Company ("PRIDCO") requesting the accelerated
repayment of a grant that MOVA received in 1996. In accordance with the terms
of the original agreement with PRIDCO, MOVA has been repaying the grant in the
form of royalty payments that are tied to revenues generated from specific
products that MOVA manufactures for its clients. Such royalty payments are
charged to earnings as they are incurred.
The Company is in the process of investigating whether the accelerated
repayment of the grant is the responsibility of the previous owners of MOVA.
Because of the uncertainty of the outcome of these investigations, no
liability has been recorded on the balance sheet at April 30, 2006. The amount
outstanding on the grant at April 30, 2006 is $4,749,000.
Critical Accounting Policies and Estimates
General
Patheon's significant accounting policies are described in Note 1 to the
2005 audited consolidated financial statements. The most critical of these
policies are those related to revenue recognition, deferred revenues,
intangible assets, goodwill, employee future benefits, and income taxes,
(Notes 1, 6, 8, 12 and 16 of the 2005 audited consolidated financial
statements).
The preparation of the consolidated financial statements requires
management to make estimates and assumptions that affect the reported amounts
of assets, liabilities, revenues and expenses. These estimates and assumptions
are based upon management's historical experience and are believed by
management to be reasonable under the circumstances. Such estimates and
assumptions are evaluated on an ongoing basis and form the basis for making
judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results could differ significantly
from these estimates.
The Company's Accounting Policies have been reviewed and discussed with
the Company's Audit Committee.
Revenue Recognition
The Company recognizes revenue for its commercial manufacturing and
pharmaceutical development services when services are completed in accordance
with specific agreements with its clients and when all costs connected with
providing these services have been incurred, the price is fixed or
determinable and collectibility is reasonably assured. Client deposits on
pharmaceutical development services in progress are included in accounts
payable and accrued liabilities.
The Company does not receive any fees on signing of contracts. In the
case of pharmaceutical development services, revenue is recognized on the
achievement of specific milestones. In the case of commercial manufacturing
services, revenue is recognized when services are complete and the product has
met rigorous quality assurance testing.
Deferred Revenues
The costs of certain capital assets are reimbursed to the Company by the
pharmaceutical companies that are to benefit from the improvements in
connection with the manufacturing and packaging agreements in force. These
reimbursements are recorded as deferred revenues and are recognized as income
over the remaining minimum term of the agreements. During the second quarter
of 2006, $0.5 million was recognized as earnings. During the first six months
of 2006, $1.0 million was recognized as earnings.
Intangible Assets
Intangible assets represent the values assigned to acquired client
contracts and relationships. They are amortized on a straight-line basis over
nine years. During the second quarter of 2006, $3.5 million was charged to
earnings. During the first six months of 2006, $6.9 million was charged to the
loss.
On an ongoing basis, the Company reviews whether there are any indicators
of impairment. If such indicators are present, the Company assesses the
recoverability of intangible assets by determining whether the carrying value
of such assets can be recovered through undiscounted future cash flows. If the
sum of undiscounted future cash flows is less than the carrying amount, the
excess of the carrying amount over the estimated fair value, based on
discounted future cash flows, is recorded as a charge to net earnings. No
amounts in connection with impairment were charged to earnings in the second
quarter of 2006, nor to the net loss in the first six months of 2006.
Valuation of Goodwill
The Company evaluates goodwill for impairment at least annually and
reviews if there are any indicators of impairment on an ongoing basis. If the
carrying value of the reporting unit exceeds the reporting unit's fair value,
any excess represents an impairment loss.
The goodwill shown on the financial statements for the period ended April
30, 2006 was $190.9 million and relates to the acquisition in 2000 of the
remaining shares of Global Pharm Inc., which now operates as Toronto York
Mills Operations, and from the acquisition of MOVA on December 23, 2004. As at
April 30, 2006, goodwill shown on the financial statements relating to the
MOVA acquisition was $187.8 million and goodwill shown relating to Toronto
York Mills acquisition was $3.1 million.
Income Taxes
In accordance with Canadian GAAP, the Company uses the liability method
of accounting for future income taxes and provides for future income taxes for
significant temporary timing differences.
Preparation of the consolidated financial statements requires an estimate
of income taxes in each of the jurisdictions in which the Company operates.
The process involves an estimate of the Company's current tax exposure and an
assessment of temporary differences resulting from differing treatment of
items such as depreciation and amortization for tax and accounting purposes.
These differences result in future tax assets and liabilities and are
reflected in the consolidated balance sheet.
Future tax assets of $32.7 million have been recorded at April 30, 2006.
This amount includes $11.9 million relating to investment tax credits arising
from Scientific Research and Experimental Development claims in the Canadian
operations, that were recorded in accounts receivable in prior periods. The
future tax assets are also primarily composed of accounting provisions related
to pension and post-retirement benefits not currently deductible for tax
purposes, the tax benefit of net operating loss carry forwards related to the
U.K. and Canadian operations and share issue costs in relation to the
acquisition of MOVA. The Company evaluates quarterly the ability to realize
its future tax assets. The factors used to assess the likelihood of
realization are the Company's forecast of future taxable income and available
tax planning strategies that could be implemented to realize the future tax
assets. The Company has available to it tax planning strategies to realize
future tax assets in order to avoid the potential loss of benefits.
Future tax liabilities of $39.8 million have been recorded at
April 30, 2006. This liability has arisen primarily on tax depreciation in
excess of book depreciation.
The Company's tax filings are subject to audit by taxation authorities.
Although management believes that it has adequately provided for income taxes
based on the information available, the outcome of audits cannot be known with
certainty and the potential impact on the financial statements is not
determinable.
Employee Future Benefits
The Company provides pensions and post-employment benefits, including
medical benefits and dental care. The determination of the obligation and
expense for defined benefit pensions and post-employment benefits is dependent
on the selection of certain assumptions used by actuaries in calculating such
amounts. Those assumptions are disclosed in Note 12 to the Company's 2005
audited consolidated financial statements.
Variable Interest Entities
The Company has adopted Accounting Guideline 15 "Consolidation of
Variable Interest Entities". The Guideline requires consolidation of entities
that are deemed to be subject to control on a basis other than through
ownership of a voting interest in the entity. The Company has concluded that
it does not have any variable interest entities and there is no impact on the
consolidated financial statements as a result of adopting the Guideline.
Risk Management
The following are updates to certain of the risks and uncertainties
described in the Management's Discussion and Analysis section of Patheon's
2005 Annual Report, available on SEDAR (www.sedar.com) or on Patheon's website
(www.patheon.com).
Foreign Currency
The Company's business activities are conducted in several currencies -
Canadian dollars and U.S. dollars for the Canadian operations, U.S. dollars
for the U.S. operations and euros and U.K. sterling for the European
operations.
Since the European and U.S. operations conduct business principally in
their respective local currencies, the exposure to foreign currency gains and
losses is not significant. However, the Company's Canadian operations
negotiate sales contracts for payment in both U.S. and Canadian dollars, and
materials and equipment are purchased in both U.S. and Canadian dollars. The
majority of its non-material costs (including payroll, facilities' costs and
costs of locally sourced supplies and inventory) are denominated in Canadian
dollars. Approximately 65% to 75% of revenues of the Canadian operations and
approximately 15% to 25% of its operating expenses are transacted in U.S.
dollars. As a result, the Company may experience trading and translation gains
or losses because of volatility in the exchange rate between the Canadian
dollar and the U.S. dollar. Based on the Company's current U.S. denominated
net inflows, for each one-cent change in the Canadian-U.S. rate, the impact on
annual net earnings is approximately $0.7 million.
The Company mitigates its foreign exchange risk by engaging in foreign
currency hedging activities using derivative financial instruments. At April
30, 2006 the Company had outstanding foreign exchange contracts to sell
US$35 million. The contracts mature at the latest on September 27, 2006 and
the mark-to-market value at April 30, 2006 was an unrealized gain of
$1.4 million. The Company does not purchase any derivative instruments for
speculative purposes.
Translation gains and losses related to the carrying value of the
Company's foreign operations and certain foreign denominated debt held by the
Company as a hedge against the carrying value of certain foreign operations,
are deferred and included in the cumulative translation account in
shareholders' equity. At April 30, 2006, the balance in the account was a
$68.1 million gain compared with a $17.9 million gain at April 30, 2005.
Interest Rate Exposure
The Company has exposure to movements in interest rates. During the
second quarter of 2006, the Company unwound the interest rate swap contracts
that were put in place during the first quarter of 2006 to convert
$107.5 million of debt drawn on the Company's new North American term
facilities from floating interest rates to fixed interest rates. The Company
realized a gain of $1.1 million on the unwinding of the swap. The gain is
being amortized as a credit to the interest expense over six years, reflecting
the term of the original swap contracts.
At April 31, 2006, 95% of the Company's total debt portfolio was subject
to movements in floating interest rates. Assuming no change to the structure
of the debt portfolio, a 1% change in floating interest rates has an impact on
annual net earnings of approximately $1.8 million.
The Company continues to monitor floating and long-term interest rates
and may enter into new arrangements in the future that reduce the Company's
exposure to changes in floating interest rates.
Additional Information
Share Capital
As of April 30, 2006, the Company had 92,845,688 common shares
outstanding.
Public Securities Filings
Other information about the Company, including the annual information
form and other disclosure documents, reports, statements or other information
that is filed with Canadian securities regulatory authorities can be accessed
through SEDAR at www.sedar.com.
Outlook
In the second half of 2006, the Company expects continuing improvements
in its commercial manufacturing businesses in Canada and Europe. In Canada,
operating efficiencies at Whitby that were starting to be realized in the
second quarter are expected to continue through the balance of the year and
the Company expects to have completely worked through the back order position
at the site by the fourth quarter. The Toronto Region Operations will continue
to benefit from higher volumes of high-potency products, including those that
were launched for clients in 2005, while in Europe, revenue growth will be
driven by the two carve-out initiatives in France and Italy and from
additional sterile volumes in Italy. Collectively, these carve-outs reflect
25 products in more than 900 dosage and packaging formats. To date, 6 products
have been transferred to Patheon's Italian facilities and 3 to its facility in
Bourgoin-Jallieu, France, including 3 in the second quarter. The transfers
will be completed in 2007 and in total are expected to contribute in the range
of $35 million to $40 million to the revenue base of Patheon's European
operations in 2008.
Revenues from commercial operations in the U.S., including Puerto Rico,
are expected to be lower in the second half of the year compared with 2005,
reflecting a decline in base business volumes in Caguas, Manati and
Cincinnati, offset in part by continuing volume and manufacturing efficiency
improvements in Carolina. While revenues from the manufacturing of Zocor(R)
are expected to decline as a result of its patent expiry in June 2006, the
full impact will be deferred until 2007, as the Company expects to manufacture
an authorized generic version of the product for at least the six months
following the patent expiry. In the first six months of 2006 Zocor(R)
represented less than 3% of the Company's consolidated revenues. Revenues from
the branded and generic versions of the product in the second half of 2006 are
expected to be approximately one-third lower than in the first half of the
year.
In the PDS operations, the Company expects that revenue growth will
accelerate in the second half of the year, driven by gains in the Cincinnati
and Swindon PDS operations.
Overall, revenues in the second half of 2006 are expected to be slightly
higher than 2005, but EBITDA will be similar, due to the impact of the
continuing strength of the Canadian dollar relative to the US dollar. This has
the effect of reducing the profitability of the Canadian operations, where
most of the revenues are denominated in U.S. dollars, but costs are largely
incurred in Canadian dollars. Depreciation, amortization and interest costs
will be marginally higher than the second quarter run rate. Effective tax
rates will be impacted largely by changes in profitability in the Puerto Rican
and Italian operations. The effective tax rate in the third quarter is
expected to be in the 50% - 55% range, reflecting the expectation of
increasing earnings in Italy and continuing pre-tax losses in Puerto Rico. The
effective tax rate in the fourth quarter is expected to be in the 40% - 45%
range as the Puerto Rico operations are expected to return to profitability.
No Auditor Review
The accompanying unaudited interim financial statements of the Company
have been prepared by and are the responsibility of management. The Company's
independent auditor has not performed a review of the financial statements for
the three-month and six-month periods ended April 30, 2006 or for the
comparative periods ended April 30, 2005.
FORWARD-LOOKING STATEMENTS
This news release and MD&A contains forward-looking statements which
reflect management's expectations regarding the Company's future growth,
results of operations, performance (both operational and financial) and
business prospects and opportunities. Wherever possible, words such as
"plans," "expects" or "does not expect," "forecasts," "anticipates" or "does
not anticipate," "believes," "intends" and similar expressions or statements
that certain actions, events or results "may", "could", "would", "might" or
"will" be taken, occur or be achieved have been used to identify these
forward-looking statements. Although the forward-looking statements contained
in this news release and MD&A reflect management's current assumptions based
upon information currently available to management and based upon what
management believes to be reasonable assumptions, the Company cannot be
certain that actual results will be consistent with these forward-looking
statements. Forward-looking statements necessarily involve significant known
and unknown risks, assumptions and uncertainties that may cause the Company's
actual results, performance, prospects and opportunities in future periods to
differ materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among other things: the
market demand for client products; dependence on key clients; the ability to
identify and secure new contracts; regulatory matters, including compliance
with pharmaceutical regulations; management of expanded operations;
international operations risks; currency risks; competition; product liability
claims; integration of new operations; financing risks and interest rate
risks. Although the Company has attempted to identify important risks and
factors that could cause actual actions, events or results to differ
materially from those described in forward-looking statements, there may be
other factors and risks that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that
forward-looking statements will prove to be accurate, as actual results and
future events could differ materially from those anticipated in such
statements. Accordingly, readers should not place undue reliance on
forward-looking statements. These forward-looking statements are made as of
the date of this news release and MD&A and, except as required by law, the
Company assumes no obligation to update or revise them to reflect new events
or circumstances.
>>
%SEDAR: 00001700E